News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|October 19, 2021

Treatment Options for Bipolar Disorder

Author(s)Michael E. Thase, MD, Gustavo Alva, MD, DFAPA, Theresa Cerulli, MD

Psychiatric experts consider mood stabilizers when treating bipolar disorder and review the role of antidepressants in disease management.

Episodes in this series

EP. 1 Patient Case #1: 27-Year-Old Woman With Bipolar Disorder

EP. 1 Patient Case #1: 27-Year-Old Woman With Bipolar Disorder

EP. 2 Clinical Significance of Bipolar Disorder

EP. 2 Clinical Significance of Bipolar Disorder

EP. 3 Clinical Impressions From Patient Case #1

EP. 3 Clinical Impressions From Patient Case #1

EP. 4 Diagnosis of Bipolar Disorder

EP. 4 Diagnosis of Bipolar Disorder

EP. 5 Treatment Options for Bipolar Disorder

EP. 5 Treatment Options for Bipolar Disorder

EP. 6 Patient Case #2: 47-Year-Old Man With Treatment Resistant Depression (TRD)

EP. 6 Patient Case #2: 47-Year-Old Man With Treatment Resistant Depression (TRD)

EP. 7 Patient Case #2 Continued: Novel Second-Generation Antipsychotics

EP. 7 Patient Case #2 Continued: Novel Second-Generation Antipsychotics

EP. 8 Role of Telemedicine in Bipolar Disorder

EP. 8 Role of Telemedicine in Bipolar Disorder

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

February theme

Presenting Our February 2026 Theme: Bipolar Disorder

February 2nd 2026

bipolar

Phase 2 Trial Initiated: LB-102 for Bipolar Depression

January 26th 2026

brain

sNDA Submission: Igalmi for Acute Treatment of Agitation Associated With Bipolar Disorders or Schizophrenia in Outpatient Setting

January 20th 2026

New Year’s Resolutions and Bipolar Disorder: Insights from Jo Hughes, DSMc, PA-C, CAQ-PSYCH

ByJo A. Hughes, DMSc, PA-C, CAQ-PSY,Jessica Walters

January 1st 2026

Programs for ST-905 and ST-905 for Schizophrenia and Depression Launched by Syremis Therapeutics

ByJessica Walters

December 24th 2025

Latest CME

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Optimizing Care for Patients With Tardive Dyskinesia

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Trending on Psychiatric Times

Depression and Long COVID Outcomes in Women: New Data Analysis

Patterns of Propensity: A Review of Heinrichs’ How Psychiatrists Make Decisions

Investigational Psilocybin for PTSD and Ongoing Trials

Extension of Expanded Access Program for Zervimesine to Treat Dementia With Lewy Bodies

Why Global Integration Is Essential for the Future of DSM